Ocugen Inc (OCGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocugen Inc (OCGN) has a cash flow conversion efficiency ratio of -3.754x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.79 Million) by net assets ($5.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Ocugen Inc fund operations to measure how many days the company can operate on defensive assets alone.
Ocugen Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocugen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ocugen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocugen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
D.B.Corp Limited
NSE:DBCORP
|
0.031x |
|
COSCO SHIPPING Development Co. Ltd.
F:EZ5
|
0.102x |
|
Cloudberry Clean Energy As
OL:CLOUD
|
0.045x |
|
Altshuler Shaham Financial LTD
TA:ALTF
|
0.052x |
|
K-Bro Linen Inc.
TO:KBL
|
0.082x |
|
Development Investment Construction JSC
VN:DIG
|
0.114x |
|
Ege Endustri ve Ticaret AS
IS:EGEEN
|
0.030x |
|
PHOENIX N AG
SW:PMN
|
0.080x |
Annual Cash Flow Conversion Efficiency for Ocugen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocugen Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Ocugen Inc (OCGN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.17 Million | $-56.96 Million | 4.682x | +429.23% |
| 2024-12-31 | $29.63 Million | $-42.14 Million | -1.422x | +7.03% |
| 2023-12-31 | $40.56 Million | $-62.05 Million | -1.530x | -88.38% |
| 2022-12-31 | $73.98 Million | $-60.08 Million | -0.812x | -62.31% |
| 2021-12-31 | $95.82 Million | $-47.94 Million | -0.500x | +26.70% |
| 2020-12-31 | $21.55 Million | $-14.71 Million | -0.683x | +55.48% |
| 2019-12-31 | $11.02 Million | $-16.89 Million | -1.533x | -104.45% |
| 2018-12-31 | $-458.00K | $-15.78 Million | 34.448x | +1586.17% |
| 2017-12-31 | $-11.27 Million | $-23.02 Million | 2.043x | +207.70% |
| 2016-12-31 | $13.57 Million | $-25.74 Million | -1.897x | -78.10% |
| 2015-12-31 | $28.20 Million | $-30.03 Million | -1.065x | -213.69% |
| 2014-12-31 | $54.21 Million | $-18.41 Million | -0.340x | -267.87% |
| 2013-12-31 | $-75.55 Million | $-15.28 Million | 0.202x | -67.41% |
| 2012-12-31 | $-19.71 Million | $-12.23 Million | 0.621x | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more